Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 10/2018

01-10-2018 | Original Article

Reality of the emetogenic level of irinotecan

Authors: Maria-Angeles Garcia-del-Barrio, Salvador Martin-Algarra, Azucena Aldaz Pastor

Published in: Supportive Care in Cancer | Issue 10/2018

Login to get access

Abstract

Purpose

To assess the emetogenic potential of different chemotherapy (CT) regimens in daily clinical practice in an outpatient setting. To optimize antiemetic prophylaxis if necessary

Methods

Prospective and retrospective review of the emetogenic potential of CT regimens used in adult patients in an outpatient setting

Results

We assess the chemotherapy-induced nausea and vomiting (CINV) of 50 different CT regimens used on 157 different patients in an outpatient setting. We found that the CT usually classified as highly emetogenic, including cisplatin and anthracycline-cyclophosphamide combination, had the higher incidence of CINV (37.5 and 54.4% respectively). The antineoplastic drugs usually considered to be moderately emetogenic had, as expected, lower rates of emesis with the exception of irinotecan, which presented a pattern of nausea and/or vomiting (NV) similar to the highly emetogenic CT with a global incidence of 48.5%. The appearance of emetic symptoms had impact on quality of life in 70% of the patients, with nausea being the main emetic symptom.

Conclusion

Antiemetic prophylaxis for highly emetogenic CT could be improve. Irinotecan CT regimens have a high emetogenic potential more than moderate and require more intensive antiemetic prophylaxis too.
Literature
1.
Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4:191–196PubMed
2.
Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, du Bois A, Tonato M (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update. Support Care Cancer 13:80–84CrossRefPubMed
3.
Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21:S232–S243CrossRef
4.
Basch E, Prestrud AA, Hesketh PJ, American Society of Clinical Oncology et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189–4198CrossRefPubMedPubMedCentral
5.
Grunberg S, Warr D, Gralla R et al (2011) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art. Support Care Cancer 19:S43–S47CrossRefPubMed
6.
Jordan K, Chan A, Gralla R et al (2017) 2016 updated MASCC/ESMO consensus recommendations: emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Support Care Cancer 25:271–275CrossRefPubMed
7.
Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M (2017) NCCN guidelines insights: antiemesis, version 2.2017. J Natl Compr Cancer Netw 15:883–893CrossRef
8.
Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26:1081–1090CrossRefPubMed
9.
10.
Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom Manag 34:148–159CrossRef
11.
Martin A, Pearson J, Cai B, Elmer M, Horgan K, Lindley C (2003) Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 11:522–527CrossRefPubMed
12.
Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiat Scand 67:361–370CrossRefPubMed
13.
Dranitsaris G, Joy A, Young S et al (2009) Identifying patients at high risk for nausea and vomiting after chemotherapy: development of a practical prediction tool I. Acute nausea and vomiting. J Support Oncol 7:1–8
14.
Petrella T, Clemons M, Joy A et al (2009) Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical validated prediction tool II. Delayed nausea and vomiting. J Support Oncol 7:9–16
15.
Junker A, Wiedemann G (1999) Antiemetic guidelines: a cooperation between a non-university hospital (Klinikum Remscheid) and a university center (Medical University of Lübeck) in Germany. J Oncol Pharm Pract 5:125–127CrossRef
16.
Molassiotis A, Stamataki Z, Kontopantelis E (2013) Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting. Support Care Cancer 21:2759–2767CrossRefPubMed
17.
Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, Jordan K, Young A, Aapro M (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol 28:1260–1267CrossRefPubMedPubMedCentral
18.
Silvestris N, Brunetti AE, Russano N, Narduli P (2013) Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX. Support Care Cancer 21:2955–2956CrossRefPubMed
19.
20.
Roscoe JA, Morrow GR, Colagiuri B, Heckler CE, Pudlo BD, Colman L, Hoelzer K, Jacobs A (2010) Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer 18:869–876CrossRefPubMed
21.
Olver I, Molassiotis A, Aapro M et al (2011) Antiemetic research: future directions. Support Care Cancer 19:S49–S55CrossRefPubMed
22.
Nieva J, Webb W, Siuzdak G (2007) Pharmacokinetic effect of aprepitant on irinotecan in patients with colorectal cancer. J Clin Oncol 25:S19622
23.
Sanger G, Andrews P (2006) Treatment of nausea and vomiting: gaps in our knowledge. Auton Neurosci 129:3–16CrossRefPubMed
24.
Glaus A, Knipping C, Morant R, Böhme C, Lebert B, Beldermann F, Glawogger B, Ortega PF, Hüsler A, Deuson R (2004) Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 12:708–715CrossRefPubMed
25.
Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, Cruciani G, di Maio M, Andrea B, Deuson RR (2007) The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer 15:179–185CrossRefPubMed
Metadata
Title
Reality of the emetogenic level of irinotecan
Authors
Maria-Angeles Garcia-del-Barrio
Salvador Martin-Algarra
Azucena Aldaz Pastor
Publication date
01-10-2018
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 10/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4196-z

Other articles of this Issue 10/2018

Supportive Care in Cancer 10/2018 Go to the issue

Review Article

The pathophysiology of cancer-related fatigue: current controversies

Original Article

Cancer care in regional Australia from the health professional’s perspective

Original Article

Increasing provider awareness of and recommendations for yoga and meditation classes for cancer patients

Original Article

A two-dimensional model of disrupted body integrity: initial evaluation in head and neck cancer

Original Article

The effects of an educational program for non-physician health care providers regarding fertility preservation

Original Article

The utility and efficacy of self-expandable metal stents for treating malignant gastric outlet obstructions in patients under best supportive care
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits